tesidolumab

Home
Ligands
tesidolumab

GtoPdb Ligand ID: 8711

Synonyms: LFG-316 | LFG316

Comment: Tesidolumab is a fully human monoclonal antibody targeting complement C5. Like eculizumab, this investigational monoclonal inhibits terminal complement activation.
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence alignment analysis using the heavy and light variable domains of tesidolumab provide 100% matches to SEQ ID NOs 7 and 8 respectively from patent US8241628 [1]. These peptide sequences correspond to antibody (MOR0)8109 in said patent.

Summary
Biological activity
Clinical data
References

References
1. Diefenbach-Streiber B, Eberth A, Guild BC, Kim Y-I, Roguska M, Splawski I. (2012) Compositions and methods for antibodies targeting complement protein C5. Patent number: US8241628 B2. Assignee: Novartis Ag.. Priority date: 05/07/2008. Publication date: 14/07/2012.

References

1. Diefenbach-Streiber B, Eberth A, Guild BC, Kim Y-I, Roguska M, Splawski I. (2012)
Compositions and methods for antibodies targeting complement protein C5.
Patent number: US8241628 B2. Assignee: Novartis Ag.. Priority date: 05/07/2008. Publication date: 14/07/2012.